Calidi Biotherapeutics announced that its 2025 Annual Report included an audit report with an explanatory paragraph highlighting the assumption that the company will continue as a going concern. This disclosure is mandated by the NYSE American Company Guide and does not indicate any changes to previous filings. The company is advancing its pipeline of targeted genetic medicines, including its lead candidate CLD-401 for cancers, with ongoing studies and planned clinical trials. Investors should note the forward-looking statements about potential risks and milestones in Calidi's development programs.
Silvercorp Metals Inc. announced a semi-annual dividend of US$0.0125 per share, payable to shareholders of record on June 5, 2026, with payment scheduled by June 25, 2026. The dividend is eligible for Canadian tax purposes. The company, a Canadian mi...
Oura Health is preparing for an IPO that could indicate whether public markets are ready to support consumer-focused digital health companies. Unlike earlier wearables focused on hardware sales, Oura emphasizes a subscription model offering health in...
Richmond Mutual Bancorporation, a community-focused bank holding company based in Indiana, announced a quarterly cash dividend of $0.15 per share. The dividend will be paid on June 17, 2026, to shareholders recorded as of June 3, 2026. This dividend ...
Zimmer Biomet Holdings, a global leader in medical technology, announced a quarterly cash dividend of $0.24 per share for the second quarter of 2026. The dividend will be paid on or about July 31, 2026, to shareholders of record as of June 25, 2026. ...
Alerus Financial Corporation announced a 4.76% increase in its regular quarterly cash dividend to $0.22 per common share. The dividend will be paid on July 10, 2026, to shareholders recorded by June 26, 2026. This increase reflects the company's ongo...
